Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice

• Status: Completed
• Trial end date: 2017-05-31
• Target enrollment: 0
• Participant gender: Female

Summary

This survey is conducted for preparing application material for re examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and efficacy profiles of VIVIANT in usual practice according to the Re-examination Regulation for New Drugs

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Bazedoxifene

Criteria

Inclusion Criteria:

• Postmenopausal osteoporosis and osteopenia patients

Exclusion Criteria:

• Patients with active or past history of venous thromboembolic events including deep vein thrombosis,

• Patients with pulmonary embolism and retinal vein thrombosis